2015-16年喀麦隆新诊断个体中基于干血斑的下一代测序方法检测的传播性HIV-1耐药低流行率
在喀麦隆四家城市医院纳入360例新诊断HIV-1个体,采用手指采血干血斑样本的下一代测序法检测传播性耐药突变。82.8%(298/360)获得基线耐药数据,核苷类逆转录酶抑制剂、非核苷类逆转录酶抑制剂和蛋白酶抑制剂耐药突变率分别为3.0%、4.0%和1.3%。与已知HIV-1阳性者发生无保护性行为与耐药突变传播显著相关(校正OR 9.6;95%CI 1.79-51.3)。
要点
- 2015-16年喀麦隆研究点传播性HIV-1耐药流行率目前较低。
- 干血斑结合下一代测序可成功获得82.8%新诊断者的耐药数据。
- 与已知HIV-1阳性者无保护性行为与耐药突变传播显著相关(校正OR 9.6;95%CI 1.79-51.3)。
核心结论
- 研究地点喀麦隆的传播性HIV-1耐药流行率目前较低,但一些危险性行为提示公共卫生问题,可能影响预防新发HIV-1感染。
研究设计与样本
- 多中心研究,在喀麦隆四个城市地区的医院于2015-16年纳入360例新诊断HIV-1个体,采集手指采血干血斑样本和问卷。
- 开发了适用于干血斑样本及HIV-1 M、N和O组基因组的HIV-1蛋白酶和逆转录酶耐药基因分型检测方法。
- 使用世界卫生组织2009年传播性耐药HIV毒株监测突变列表分析传播性耐药突变。
主要发现
- 应用「干血斑-下一代测序-基因型耐药检测」,从82.8%(298/360)的新诊断个体成功获得基线HIV-1耐药数据。
- 在核苷酸频率>15%时,核苷类逆转录酶抑制剂耐药突变见于3.0%(9/298),非核苷类逆转录酶抑制剂耐药突变见于4.0%(12/298),蛋白酶抑制剂耐药突变见于1.3%(3/240)。
- 最常检测到的非核苷类逆转录酶抑制剂突变是K103N(2.7%)。
- 将分析扩展至低丰度传播性耐药突变(即3%-15%),额外识别出12例(4.0%)携带传播性耐药突变的个体。
- 与已知HIV-1阳性者发生无保护性行为与耐药突变传播显著相关(校正OR 9.6;95%CI 1.79-51.3)。
关键数值与推荐
- 传播性耐药突变分析采用世界卫生组织2009年传播性耐药HIV毒株监测突变列表。
- 耐药突变报告阈值:核苷酸频率>15%时,核苷类逆转录酶抑制剂耐药3.0%(9/298),非核苷类逆转录酶抑制剂耐药4.0%(12/298),蛋白酶抑制剂耐药1.3%(3/240)。
- 低丰度传播性耐药突变范围为3%-15%,额外识别12例(4.0%)。
- 与已知HIV-1阳性者无保护性行为与耐药突变传播相关:校正OR 9.6;95%CI 1.79-51.3。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To determine the most recent prevalence, transmission patterns and risk factors of transmitted drug-resistance mutations (TDRMs) in Cameroon, we initiated a multicentre study monitoring HIV-1 drug resistance in newly HIV-1-diagnosed individuals using a novel next-generation sequencing (NGS) assay applicable to fingerprick dried blood spot (DBS) samples. METHODS: Fingerprick DBS samples and questionnaires were collected from 360 newly HIV-1-diagnosed individuals in four hospitals in urban areas in Cameroon in the years 2015-16. We developed an HIV-1 protease and reverse transcriptase drug resistance genotyping assay applicable to DBS samples and HIV-1 genomes of groups M, N and O. The WHO 2009 list of mutations for surveillance of transmitted drug-resistant HIV strains was used to analyse TDRMs. RESULTS: Applying our 'DBS-NGS-genotypic resistance test', baseline HIV-1 drug resistance data were successfully obtained from 82.8% (298/360) of newly diagnosed individuals. At nucleotide frequencies >15%, TDRMs to NRTIs were observed in 3.0% (9/298), to NNRTIs in 4.0% (12/298) and to PIs in 1.3% (3/240). The NNRTI mutation K103N was most commonly detected (2.7%). Expanding the analysis to low-abundance TDRMs, i.e. 3%-15%, 12 additional individuals (4.0%) harbouring TDRMs were identified. Having unprotected sex with a known HIV-1-positive person was significantly associated with the transmission of DRMs (adjusted OR 9.6; 95% CI 1.79-51.3). CONCLUSIONS: The prevalence of transmitted HIV-1 drug resistance is currently low in the study sites in Cameroon. Evidence of some risky sexual behaviours depicts a public health problem with possible implications for the prevention of new HIV-1 infections.
引用
- Mbunkah HA, Marzel A, Schmutz S, et al. Low prevalence of transmitted HIV-1 drug resistance detected by a dried blood spot (DBS)-based next-generation sequencing (NGS) method in newly diagnosed individuals in Cameroon in the years 2015-16. J Antimicrob Chemother. 2018. PMID: 29635462. doi:10.1093/jac/dky103
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。